(0.59%) 5 158.16 points
(0.14%) 38 731 points
(0.74%) 16 275 points
(0.74%) $78.69
(3.83%) $2.22
(1.05%) $2 332.90
(3.46%) $27.61
(-0.14%) $963.95
(-0.11%) $0.928
(-0.41%) $10.83
(-0.21%) $0.795
(-0.12%) $91.34
2 days till quarter result
(bmo 2024-05-08)
Expected move: +/- 12.01%
-0.27% $ 11.05
Live Chart Being Loaded With Signals
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids...
Stats | |
---|---|
Volumen de hoy | 6 924.00 |
Volumen promedio | 14 118.00 |
Capitalización de mercado | 13.67M |
EPS | $0 ( 2024-04-03 ) |
Próxima fecha de ganancias | ( $-0.120 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.510 |
ATR14 | $0.110 (1.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-06-21 | Barbier Ann | Buy | 40 000 | Stock Option (right to buy) |
2023-06-21 | Geraghty James A | Buy | 45 000 | Stock Option (right to buy) |
2023-06-21 | Kiener Peter A | Buy | 40 000 | Stock Option (right to buy) |
2023-06-21 | Kiritsy Christopher P | Buy | 40 000 | Stock Option (right to buy) |
2023-06-21 | Richman Michael | Buy | 40 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
16.72 |
Last 97 transactions |
Buy: 6 636 987 | Sell: 4 508 050 |
Volumen Correlación
Pieris Pharmaceuticals Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Pieris Pharmaceuticals Correlación - Moneda/Commodity
Pieris Pharmaceuticals Finanzas
Annual | 2023 |
Ingresos: | $42.81M |
Beneficio Bruto: | $41.03M (95.84 %) |
EPS: | $-21.80 |
FY | 2023 |
Ingresos: | $42.81M |
Beneficio Bruto: | $41.03M (95.84 %) |
EPS: | $-21.80 |
FY | 2022 |
Ingresos: | $25.90M |
Beneficio Bruto: | $23.12M (89.27 %) |
EPS: | $-0.420 |
FY | 2021 |
Ingresos: | $31.42M |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-0.675 |
Financial Reports:
No articles found.
Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico